Compare Stocks: SCYX, SBTX, SLGL, and IMUX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$12.74 -2.8%	$14.86	$5.06 ▼ $17.43	$178.87M	1.41	230,496 shs	405,016 shs
SBTX Silverback Therapeutics	$5.62 -0.9%	$6.42	$2.80 ▼ $8.97	$202.65M	0.6	337,931 shs	852,847 shs
SCYX SCYNEXIS	$5.15 -2.8%	$4.78	$3.53 ▼ $10.48	$52.73M	1.11	81,024 shs	33,068 shs
SLGL Sol-Gel Technologies	$69.37 -0.2%	$78.24	$23.13 ▼ $97.97	$195.34M	1.12	65,910 shs	38,593 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	0.00%	-17.03%	-8.32%	+6.93%	+72.27%
SBTX Silverback Therapeutics	0.00%	-4.58%	-8.77%	-34.35%	-44.19%
SCYX SCYNEXIS	0.00%	+1.34%	+1.15%	+21.56%	-25.56%
SLGL Sol-Gel Technologies	0.00%	+0.61%	-21.00%	-8.79%	+148.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$12.74 -2.8%	$14.86	$5.06 ▼ $17.43	$178.87M	1.41	230,496 shs	405,016 shs
SBTX Silverback Therapeutics	$5.62 -0.9%	$6.42	$2.80 ▼ $8.97	$202.65M	0.6	337,931 shs	852,847 shs
SCYX SCYNEXIS	$5.15 -2.8%	$4.78	$3.53 ▼ $10.48	$52.73M	1.11	81,024 shs	33,068 shs
SLGL Sol-Gel Technologies	$69.37 -0.2%	$78.24	$23.13 ▼ $97.97	$195.34M	1.12	65,910 shs	38,593 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	0.00%	-17.03%	-8.32%	+6.93%	+72.27%
SBTX Silverback Therapeutics	0.00%	-4.58%	-8.77%	-34.35%	-44.19%
SCYX SCYNEXIS	0.00%	+1.34%	+1.15%	+21.56%	-25.56%
SLGL Sol-Gel Technologies	0.00%	+0.61%	-21.00%	-8.79%	+148.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMUX Immunic	3.00	Buy	$47.25	270.88% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
SCYX SCYNEXIS	2.33	Hold	$33.00	540.78% Upside
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	184.71% Upside

Current Analyst Ratings Breakdown

Latest SCYX, SBTX, SLGL, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/10/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMUX Immunic	N/A	N/A	N/A	N/A	($0.55) per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
SCYX SCYNEXIS	$20.60M	2.49	N/A	N/A	$9.07 per share	0.57
SLGL Sol-Gel Technologies	$19.39M	10.05	N/A	N/A	$8.19 per share	8.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	-41.79%	-44.15%	-32.61%	11/4/2026 (Estimated)
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	11/19/2026 (Estimated)

Latest SCYX, SBTX, SLGL, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMUX Immunic	N/A	5.05	5.05
SBTX Silverback Therapeutics	N/A	67.87	67.87
SCYX SCYNEXIS	N/A	9.65	9.65
SLGL Sol-Gel Technologies	N/A	10.37	10.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMUX Immunic	51.82%
SBTX Silverback Therapeutics	74.89%
SCYX SCYNEXIS	54.37%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
IMUX Immunic	5.49%
SBTX Silverback Therapeutics	34.40%
SCYX SCYNEXIS	4.09%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMUX Immunic	70	13.64 million	12.90 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
SCYX SCYNEXIS	60	9.95 million	9.54 million	Optionable
SLGL Sol-Gel Technologies	50	2.81 million	941,000	No Data

SCYX, SBTX, SLGL, and IMUX Headlines

Recent News About These Companies

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages

September 6 at 6:13 AM | marketbeat.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases 5,217 Shares

September 1, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 5,217 Shares of Stock

August 31, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys 35,113 Shares

August 31, 2026 | marketbeat.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | finanznachrichten.de

Sol-Gel Technologies (NASDAQ:SLGL) Posts Quarterly Earnings Results, Beats Expectations By $1.23 EPS

August 20, 2026 | marketbeat.com

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | globenewswire.com

Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday

August 14, 2026 | marketbeat.com

Sol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | Benzinga

July 23, 2026 | benzinga.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 Shares

July 11, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in Stock

July 3, 2026 | insidertrades.com

Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities

June 26, 2026 | theglobeandmail.com

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

May 30, 2026 | theglobeandmail.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

May 28, 2026 | zacks.com

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 28, 2026 | globenewswire.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of Stock

May 15, 2026 | insidertrades.com

Sol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary Shares

March 23, 2026 | quiverquant.comQ

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

March 23, 2026 | globenewswire.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates

March 19, 2026 | zacks.com

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

March 19, 2026 | globenewswire.com

This Under-the-Radar Stock Has Surged 1,300% Over the Past Year

March 13, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX, SBTX, SLGL, and IMUX Company Descriptions

Immunic NASDAQ:IMUX

$12.74 -0.37 (-2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$12.75 +0.01 (+0.08%)

As of 07:44 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Silverback Therapeutics NASDAQ:SBTX

$5.62 -0.05 (-0.88%)

As of 09/4/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

SCYNEXIS NASDAQ:SCYX

$5.15 -0.15 (-2.83%)

Closing price 04:00 PM Eastern

Extended Trading

$5.19 +0.04 (+0.82%)

As of 07:55 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Sol-Gel Technologies NASDAQ:SLGL

$69.37 -0.15 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$69.24 -0.13 (-0.18%)

As of 07:30 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCYX, SBTX, SLGL, and IMUX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCYX, SBTX, SLGL, and IMUX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCYX, SBTX, SLGL, and IMUX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX, SBTX, SLGL, and IMUX Company Descriptions

Immunic NASDAQ:IMUX

Silverback Therapeutics NASDAQ:SBTX

SCYNEXIS NASDAQ:SCYX

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCYX, SBTX, SLGL, and IMUX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCYX, SBTX, SLGL, and IMUX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCYX, SBTX, SLGL, and IMUX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX, SBTX, SLGL, and IMUX Company Descriptions

Immunic NASDAQ:IMUX

Silverback Therapeutics NASDAQ:SBTX

SCYNEXIS NASDAQ:SCYX

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools